- Home
- DOMH vs SNGX Comparison
DOMH vs SNGX Comparison
Compare DOMH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- SNGX
- Stock Information
- Founded
- DOMH 1967
- SNGX 1987
- Country
- DOMH United States
- SNGX United States
- Employees
- DOMH N/A
- SNGX N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- SNGX Health Care
- Exchange
- DOMH Nasdaq
- SNGX Nasdaq
- Market Cap
- DOMH 83.3M
- SNGX 6.5M
- IPO Year
- DOMH N/A
- SNGX 1987
- Fundamental
- Price
- DOMH $5.21
- SNGX $1.24
- Analyst Decision
- DOMH
- SNGX
- Analyst Count
- DOMH 0
- SNGX 0
- Target Price
- DOMH N/A
- SNGX N/A
- AVG Volume (30 Days)
- DOMH 302.6K
- SNGX 2.6M
- Earning Date
- DOMH 08-07-2025
- SNGX 08-08-2025
- Dividend Yield
- DOMH 6.07%
- SNGX N/A
- EPS Growth
- DOMH N/A
- SNGX N/A
- EPS
- DOMH N/A
- SNGX N/A
- Revenue
- DOMH $24,891,000.00
- SNGX $2,342.00
- Revenue This Year
- DOMH N/A
- SNGX N/A
- Revenue Next Year
- DOMH N/A
- SNGX N/A
- P/E Ratio
- DOMH N/A
- SNGX N/A
- Revenue Growth
- DOMH 630.80
- SNGX N/A
- 52 Week Low
- DOMH $0.83
- SNGX $1.20
- 52 Week High
- DOMH $13.58
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- DOMH 49.52
- SNGX 24.45
- Support Level
- DOMH $5.08
- SNGX $1.26
- Resistance Level
- DOMH $6.08
- SNGX $1.88
- Average True Range (ATR)
- DOMH 0.53
- SNGX 0.12
- MACD
- DOMH -0.04
- SNGX -0.04
- Stochastic Oscillator
- DOMH 25.45
- SNGX 0.00
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).